NEWPORT NEWS, Va., Nov. 19 Using Breast-Specific GammaImaging (BSGI) has significantly changed patient management at one breastcenter in Portland, Oregon. A group of radiologists and surgeons from LegacyHealth System recently reported that although still fairly new to BSGI, theprocedure has brought about considerable change in their practice.
Earlier this month the institution's surgical team presented data at theNorth Pacific Surgical Conference on their center's initial experienceemploying BSGI and the influence it has had on patient care. The studyreviewed 176 patient cases referred to BSGI due to one of the followingindications: suspicious clinical or mammographic findings, mammographicallydense breast tissue or a new diagnosis of breast cancer requiring additionalwork-up. Of the 47 patients with a recent breast cancer diagnosis, BSGIdetected additional disease in three patients, two with cancer in the oppositebreast and one with an additional site in the same breast. BSGI also detectedcancer in 4 of the 14 patients with a mammographic BIRADS 2 rating, typicallyindicative of benign findings such as cysts or fibroadenomas. BSGI changedpatient management in 14.7 percent of cases with another 6.8 percent whereBSGI could have helped to prevent an unneeded biopsy.
According to the authors, BSGI is playing an important role in theirbreast patient management and has the potential to help prevent unnecessarybreast biopsies and interval imaging studies for some BIRADS 3 and 4 cases.They have found it to be a useful adjunct imaging tool, especially for furtherevaluation of breast tissue in newly diagnosed breast cancer patients. One ofthe biggest benefits, they state, is that the false positive rate for BSGI wasonly 6.2 percent which is far less than studies that utilize MRI for thesetypes of patients.
About BSGI with the Dilon 6800 Gamma Camera
Breast-Specific Gamma Imaging (BSGI) performed with the Dilon 6800, is amolecular breast imaging technique that can see lesions independent of tissuedensity and discover very early stage cancers. BSGI serves as a complementarydiagnostic adjunct procedure to mammography and ultrasound for difficult-to-diagnose patients. With BSGI, the patient receives a radioactive tracing agentthat is absorbed by all the cells in the body. Cancerous cells in the breast,due to their increased rate of metabolic activity, absorb a greater amount ofthe tracing agent than normal, healthy cells and generally appear as "hotspots" on the BSGI image.
BSGI is ideal for patients with mammograms that are difficult to interpretdue to a variety of factors, such as: dense breast tissue, suspicious areas ona mammogram, lumps that can be felt but not seen with mammography orultrasound, implants and breast augmentation, scarring from previous surgeriesand for women with an increased risk of breast cancer diagnosis.
About Dilon Technologies
Dilon Technologies is bringing innovative new medical imaging products tomarket. Dilon's cornerstone product, the Dilon 6800, is a high-resolution,small field-of-view gamma camera, optimized to perform Breast-Specific GammaImaging (BSGI), a molecular breast imaging procedure which images themetabolic activity of breast lesions through radiotracer uptake. Many leadingmedical centers around the country are now offering BSGI to their patients,including: Cornell University Medical Center, New York; George WashingtonUniversity Medical Center, Washington, D.C.; Northwestern Memorial Hospital,Chicago; and The Rose, Houston. For more information on Dilon Technologiesplease visit http://www.dilon.com.
SOURCE Dilon Technologies